Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296517214> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4296517214 abstract "Abstract S4.5 Mycetoma Clinical Trial on fosravuconazole treatment in eumycetoma– Top Line Results, September 22, 2022, 10:30 AM - 12:00 PM Objective To evaluate the pharmacokinetics (PK) of fosravuconazole (measured as ravuconazole) and itraconazole in patients with mild to moderate eumycetoma caused by Madurella mycetomatis using a non-compartmental PK analysis. Methods Participants received either 200 mg or 300 mg ravuconazole once weekly or 400 mg itraconazole daily for a total duration of 12 months. Plasma concentrations of ravuconazole and itraconazole were measured on day 1 of week 1, and on weeks 2, 3, 4, and months 2, 3, 6, and 12 (at end of treatment) for analysis of population PK. The exact time of dosing on the days of sample collection, and the exact time of sample collection within the collection time window, were recorded. Plasma concentrations were quantified using Ultraperformance Liquid Chromatography with fluorescence detection (UPLC-UV). Ravuconazole and itraconazole plasma concentration-time data was performed using a standard two stage approach with non-compartmental analysis. Derived exposure parameters of ravuconazole and itraconazole, including, but not limited to, Cmax and AUC at steady state (AUCs), were calculated. The effect of covariates, such as baseline characteristics/demographics, on PK were explored. AUCs were determined when at least three subsequent samples within one dosing interval were available. Results A total of 766 samples of ravuconazole in 68 participants and 226 samples of itraconazole in 36 participants were analyzed. The average concentration of ravuconazole (range) was 3.1 mg/l (0.01-12.33 mg/l), and for itraconazole was 1.59 mg/l (0.01-5.53 mg/l). Detailed Pharmacokinetic results will be communicated and discussed in the oral presentation." @default.
- W4296517214 created "2022-09-21" @default.
- W4296517214 creator A5005268342 @default.
- W4296517214 creator A5013302584 @default.
- W4296517214 creator A5028145997 @default.
- W4296517214 creator A5032882420 @default.
- W4296517214 creator A5035723941 @default.
- W4296517214 creator A5038914371 @default.
- W4296517214 creator A5039174583 @default.
- W4296517214 creator A5039577820 @default.
- W4296517214 creator A5072332792 @default.
- W4296517214 date "2022-09-01" @default.
- W4296517214 modified "2023-09-26" @default.
- W4296517214 title "S4.5b A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan—pharmacokinetic results" @default.
- W4296517214 doi "https://doi.org/10.1093/mmy/myac072.s4.5b" @default.
- W4296517214 hasPublicationYear "2022" @default.
- W4296517214 type Work @default.
- W4296517214 citedByCount "0" @default.
- W4296517214 crossrefType "journal-article" @default.
- W4296517214 hasAuthorship W4296517214A5005268342 @default.
- W4296517214 hasAuthorship W4296517214A5013302584 @default.
- W4296517214 hasAuthorship W4296517214A5028145997 @default.
- W4296517214 hasAuthorship W4296517214A5032882420 @default.
- W4296517214 hasAuthorship W4296517214A5035723941 @default.
- W4296517214 hasAuthorship W4296517214A5038914371 @default.
- W4296517214 hasAuthorship W4296517214A5039174583 @default.
- W4296517214 hasAuthorship W4296517214A5039577820 @default.
- W4296517214 hasAuthorship W4296517214A5072332792 @default.
- W4296517214 hasBestOaLocation W42965172141 @default.
- W4296517214 hasConcept C112705442 @default.
- W4296517214 hasConcept C126322002 @default.
- W4296517214 hasConcept C16005928 @default.
- W4296517214 hasConcept C22979827 @default.
- W4296517214 hasConcept C2777071850 @default.
- W4296517214 hasConcept C2777288759 @default.
- W4296517214 hasConcept C2779548794 @default.
- W4296517214 hasConcept C2908647359 @default.
- W4296517214 hasConcept C71924100 @default.
- W4296517214 hasConcept C98274493 @default.
- W4296517214 hasConcept C99454951 @default.
- W4296517214 hasConceptScore W4296517214C112705442 @default.
- W4296517214 hasConceptScore W4296517214C126322002 @default.
- W4296517214 hasConceptScore W4296517214C16005928 @default.
- W4296517214 hasConceptScore W4296517214C22979827 @default.
- W4296517214 hasConceptScore W4296517214C2777071850 @default.
- W4296517214 hasConceptScore W4296517214C2777288759 @default.
- W4296517214 hasConceptScore W4296517214C2779548794 @default.
- W4296517214 hasConceptScore W4296517214C2908647359 @default.
- W4296517214 hasConceptScore W4296517214C71924100 @default.
- W4296517214 hasConceptScore W4296517214C98274493 @default.
- W4296517214 hasConceptScore W4296517214C99454951 @default.
- W4296517214 hasIssue "Supplement_1" @default.
- W4296517214 hasLocation W42965172141 @default.
- W4296517214 hasLocation W42965172142 @default.
- W4296517214 hasOpenAccess W4296517214 @default.
- W4296517214 hasPrimaryLocation W42965172141 @default.
- W4296517214 hasRelatedWork W2052710268 @default.
- W4296517214 hasRelatedWork W2146507402 @default.
- W4296517214 hasRelatedWork W2361287443 @default.
- W4296517214 hasRelatedWork W2371507726 @default.
- W4296517214 hasRelatedWork W2766550598 @default.
- W4296517214 hasRelatedWork W3085943042 @default.
- W4296517214 hasRelatedWork W3151787567 @default.
- W4296517214 hasRelatedWork W4225384168 @default.
- W4296517214 hasRelatedWork W4285587663 @default.
- W4296517214 hasRelatedWork W2417968062 @default.
- W4296517214 hasVolume "60" @default.
- W4296517214 isParatext "false" @default.
- W4296517214 isRetracted "false" @default.
- W4296517214 workType "article" @default.